SINO BIOPHARM(01177.HK): Deepens Exclusive Strategic Cooperation with GSK, Secures Commercialisation Rights for Two Core Innovative Respiratory Drugs

NewTimeSpace News: Sino Biopharmaceutical Limited issued a voluntary announcement dated 8 July 2026. Chia Tai Tianqing, a subsidiary of the Group, further expanded its exclusive strategic cooperation with GlaxoSmithKline (“GSK”), and acquired the exclusive commercialisation rights of two innovative respiratory medicines of GSK for mainland China, namely Trelegy Ellipta® and Anoro Ellipta®. The Group will be responsible for importation, distribution, hospital access and marketing promotion of the products, and all sales proceeds derived therefrom will be recorded as operating revenue of Chia Tai Tianqing.

Trelegy Ellipta® is a once-daily single-inhaler triple therapy. It was approved in China in 2019 for maintenance treatment of chronic obstructive pulmonary disease (COPD), and gained an additional indication for asthma maintenance therapy in 2026. It is currently the only triple therapy approved in China for maintenance treatment of both respiratory disorders, with global sales reaching GBP3 billion in 2025. Anoro Ellipta® is a dual bronchodilator, approved for COPD maintenance treatment in 2018, posting global sales of GBP542 million in 2025.

This cooperation represents a further expansion of the parties’ partnership following the liver disease collaboration reached in May 2026. China has over 100 million COPD patients and nearly 50 million asthma patients; COPD was incorporated into national basic public health service programmes in 2024. The Group stated that this cooperation will boost its revenue and profits and consolidate its leading market position in the respiratory therapeutic segment.